Key takeaway: The investor presentation for Advanced Enzyme Technologies Limited, dated August 8, 2026, provided a summary of the company's financial performance for the quarter ended June 30, 2026. Revenue increased by 2% year-on-year to ₹1,898 million, while EBITDA decreased by 10% to ₹510 million, and PAT fell by 5% to ₹386 million. The human nutrition segment, contributing 60% of total revenue, saw a 7% decline year-on-year. The animal nutrition segment decreased by 3%, while the industrial bio-processing segment grew by 30%. The presentation highlighted the company's focus on research and development, its global market presence, and strategic plans for future growth in various segments, including animal nutrition and bio-catalysis. The document also included a safe harbor statement regarding forward-looking statements and outlined the company's mission and vision.

Key takeaway: The earnings conference call for Advanced Enzyme Technologies Limited on May 12, 2026, discussed the company's financial results for the fourth quarter and fiscal year ending March 31, 2026. Management reported record revenues of INR 2,034 million for Q4, a 22% year-over-year increase, and INR 7,458 million for the full year, reflecting a 17% growth. EBITDA for Q4 was INR 632 million, up 39% YoY, with a margin of 31%. Profit after tax for Q4 reached INR 453 million, a 69% increase YoY. The Human Healthcare segment was highlighted as the largest contributor, with a 24% YoY growth in Q4. Management noted ongoing challenges in the global economy, including inflation and supply chain disruptions, but expressed confidence in maintaining growth momentum. Strategic investments in R&D and expansion into new markets were also emphasized as key focus areas for future growth.

Key takeaway: The investor presentation for Advanced Enzyme Technologies Limited, dated May 9, 2026, provided a comprehensive overview of the company's financial performance for the quarter and year ended March 31, 2026. Management reported a 22% year-on-year increase in revenue, reaching ₹2,034 million in Q4 FY26, with EBITDA growing by 39% to ₹632 million and PAT increasing by 69% to ₹453 million. For the full fiscal year, revenue rose by 17% to ₹7,458 million, EBITDA by 18% to ₹2,291 million, and PAT by 30% to ₹1,736 million. The presentation highlighted strong contributions from the human nutrition segment, which accounted for 63% of total revenue, and detailed geographical performance, noting significant growth in India and other regions. Management emphasized ongoing investments in R&D and strategic initiatives to expand market presence and product offerings.

Key takeaway: The earnings conference call for Advanced Enzyme Technologies Limited on February 4, 2026, discussed the company's financial results for the quarter and nine months ended December 31, 2025. Management reported a mixed overall performance, with a 2% year-on-year revenue growth to INR 1,719 million, but a 7% decline compared to the previous quarter. EBITDA decreased by 11% year-on-year, while profit after tax grew by 11% year-on-year to INR 432 million. Segment-wise, Human Healthcare saw a 6% decline year-on-year, while Animal Healthcare and Bioprocessing segments reported growth. Management highlighted ongoing global uncertainties, particularly due to U.S. tariffs, but expressed optimism about future growth opportunities. They emphasized a focus on operational excellence and resilience in adapting to market conditions. The call concluded with a Q&A session addressing various investor inquiries about market dynamics and future strategies.

Key takeaway: The investor presentation from Advanced Enzyme Technologies Limited, dated January 31, 2026, provided a comprehensive overview of the company's financial performance for the quarter and nine months ended December 31, 2025. The presentation reported a 2% year-on-year revenue growth to ₹1,719 million in Q3 FY26, while EBITDA decreased by 11% to ₹494 million. However, PAT increased by 11% to ₹432 million. On a year-to-date basis, revenue grew by 15% to ₹5,424 million, with EBITDA and PAT increasing by 11% and 20%, respectively. The human nutrition segment contributed 56% to total revenue but saw a 6% decline year-on-year. In contrast, the animal nutrition segment grew by 22% year-on-year. The presentation also highlighted the company's focus on R&D and its strategic plans for future growth in various segments, including probiotics and bio-catalysis.